Navigation Links
TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
Date:10/14/2010

TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization... -- TAIPEI, Taiwan, Oct. 14 /PRNewswire-Asia/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Pharmaceuticals, Licensing Click to view news release full screen  

TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic

 

TAIPEI, Taiwan, Oct. 14 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. today announced that TaiGen has entered into an amendment to its license agreement with Warner Chilcott plc regarding the development and commercialization of nemonoxacin -- a new generation quinolone antibiotic.

Under the terms of the original license agreement, entered into in December 2004, TaiGen licensed exclusive development, manufacture and commercialization rights to nemonoxacin from The Procter & Gamble Company in mainland China, Hong Kong, Taiwan, South Korea and certain other Asian countries, and assumed responsibility, at its sole cost and expense, for the conduct of a Phase Ib study and two Phase II trials in community-acquired bacterial pneumonia (CABP) and diabetic foot infection (DFI) patients, respectively, in which nemonoxacin demonstrated an excellent efficacy and safety profile. Upon Warner Chilcott's purchase of the global branded pharmaceuticals business of Procter & Gamble in October 2009, Warner Chilcott assumed Procter & Gamble's interest in the license agreement.

Under the terms of the amended agreement, entered into following the conclusion of Phase II trials, TaiGen keeps its exclusive development, manufacture and commercialization rights to nemonoxacin in the countries under the original license agreement, while Warner Chilcott retains development and commercialization rights in all other markets, including the United States and Europe. TaiGen and Warner Chilcott have agreed to cross-license their respective patent rights relating to nemonoxacin and TaiGen will transfer to Warner Chilcott its Investigational New Drug Application filed with the FDA. Upon the execution of the amended agreement, TaiGen received an upfront payment from Warner Chilcott and is eligible for certain regulatory milestone payments, as well as a royalty based on Warner Chilcott's net sales of the product.

Warner Chilcott plc is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.

"We are very encouraged by the signing of the amended agreement with Warner Chilcott," said Dr. Ming-Chu, Hsu, Chairman and CEO of TaiGen. "The deal proved TaiGen's capabilities in conducting clinical and regulatory development with high quality and at standards set by the United States Food and Drug Administration (US FDA). It also validated TaiGen's business model of building R&D portfolio through both internal R&D and external collaboration and licensing."

With China being a fast growing pharmaceutical market, TaiGen, which set up its Beijing affiliate in 2005, has been developing nemonoxacin under the China SFDA (China State Food and Drug Administration) regulation. It is expected that nemonoxacin will enter Phase III development in China very soon.

About TaiGen Biotechnology

TaiGen Biotechnology (http://www.taigenbiotech.com ) is a leading development stage pharmaceutical company based in Taiwan with a wholly-owned subsidiary in Beijing, China. The company has a full capacity in discovery research and clinical development in mainland China/Taiwan/US. Its current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market.

Media Contacts: Dr. John Jin Vice President for Business Development Tel: +886-2-8177-7072 Email: johnjin@taigenbiotech.com
'/>"/>

SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
3. TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
4. KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
7. Directors Forum: PEPFAR and the Global AIDS Response
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
11. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and PUNE, India , January 18, ... Allied Market Research, titled, "Breast Imaging Technologies Market by Type: ... global breast imaging technologies market size was valued at $2,544 ... by 2022, growing at a CAGR of 8.4% from 2016 ... Europe together accounted for over three-fourths market ...
(Date:1/18/2017)... 2017   Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies to ... reported the Company,s operating results for 2016 and an ... the Company described in its recent 10-K filing with ... accomplishments. The Company,s contract laboratory completed its evaluation of ...
(Date:1/18/2017)... DAVOS , Suiza, 18 de enero de 2017 ... biofarmacéuticas líderes lanzaron Access Accelerated, una iniciativa global para ... comunicables (NCD) y atención en países de renta baja ... NCD han alcanzado un punto de crisis, particularmente en ... casi el 80 por ciento de las muertes relacionadas ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, ... Over the past 20 years SFI has been recognized as the world’s leader in ... clients into the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, ...
(Date:1/19/2017)... ... 2017 , ... Each year, the Southeastern Society of Plastic ... of surgeons from over fifteen different countries come together to share and learn ... to breast reconstruction for breast cancer patients, teaching these surgical techniques which ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting ... global discussion about the benefits of fidgeting to relieve stress and anxiety. No ... Their Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... it from the number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating ... untreated. , Certain Dri created this infographic to explain the seven types of ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... industry’s leading journal and most-read publication among specialty pharmacists and pharmacy professionals, ... through its Strategic Alliance Partnership (SAP) program, announced Brian Haug, president of ...
Breaking Medicine News(10 mins):